reaction used to assay malondialdehyde may
1.
The formation of thromboxane B, and malondialdehyde was studied in human plateletrich plasma, in gel-filtered platelets and in bovine platelet microsomes.
2. Exogenous sodium arachidonate was converted into thromboxane B, and malondialdehyde in a concentr ation-dependent manner. Pre-incubation of platelets with aspirin inhibited the production of both thromboxane B, and malondialdehyde, although malondialdehyde could apparently be detected in the absence of thromboxane B,.
3. The aggregating agents, thrombin, collagen and the ionophore A23187 also caused production of thromboxane B, and malondialdehyde. ADP and adrenaline produced a smaller rise whilst the endoperoxide analogue U 46619 had only a slight influence on thromboxane and malondialdehyde, even though they all induced aggregation.
4. Pre-incubation of platelets with imidazole or 1-N-butylimidazole, which inhibit thromboxane synthetase, resulted in an inhibition of both thromboxane B, and malondialdehyde formation in response to collagen.
5.
The results indicate that thromboxane B, and malondialdehyde are formed in parallel, in comparable quantities. However, under the conditions used in these studies, the apparent amounts of malondialdehyde exceed those of thromboxane B,, especially in the presence of exogenous arachidonate. Thus the thiobarbiturate
Introduction
The aggregation of human platelets in response to arachidonic acid is closely associated with the formation of both prostaglandin endoperoxides (Willis, Vane, Kuhn, Scott & Petrin, 1974; Hamberg & Samuelsson, 1974 ) and of thromboxane A, (Hamberg, Svensson & Samuelsson, 1975) . These compounds are potent inducers of platelet aggregation (Hamberg et al. 1975) . Aspirin, in common with other drugs which inhibit the cyclo-oxygenase enzyme, prevents the formation of prostaglandin endoperoxides and thus inhibits aggregation induced by arachidonic acid (Smith & Willis, 1971) . It has been suggested that several aggregating agents are capable of liberating endogenous arachidonate from phospholipids in platelet membranes by activating the enzyme phospholipase A, (Bills, Smith & Silver, 1976) . The conversion of arachidonate into thromboxane A, is thought to be associated with platelet aggregation, although it is not yet clear whether the formation of thromboxane A, is a prerequisite for aggregation. (Diczfalusy, Falardeau & Hammarstrom, 1977) and intact platelets (McMillan, MacIntyre, Booth & Gordon, 1978) , it appears that the formation of thromboxane B,, malondialdehyde and hydroxyheptadecatrienoic acid may be the result of the action of the enzyme thromboxane synthetase.
In the present study, we have measured thromboxane B, and malondialdehyde concentrations under a wide variety of conditions in order to evaluate the role of thromboxane biosynthesis in platelet aggregation and to explore the potential value of these measurements as reliable indices of the formation of thromboxane by platelets in clinical disorders.
Methods and materials
Blood was obtained by venepuncture from healthy volunteer subjects who had taken no drugs for at least 10 days. Platelet-rich plasma was prepared by centrifuging citrated wholeblood [9 vol. of blood + 1 vol. of trisodium citrate (3.896, w/v)l at 200 g for 10 min. Platelet counts were adjusted to 250-300 x 109/1 by addition of platelet-poor plasma. When required, washed platelet suspensions in calcium-free Tyrode's buffer were prepared by gel-filtration of platelet-rich plasma on Sepharose 2B columns (Salzman, Lindon & Rodvien, 1976) . Platelet aggregation was measured photometrically with an ADG 1002 aggregometer (ADG Instruments Ltd, Hitchin, Herts, U.K.). Portions (190 pl) of platelet-rich plasma were incubated for 4 min at 37OC and stirred at 1200 rev./min together with 10 pl portions of test substances. For measurement of thromboxane B,, 50 pl of the platelet incubation mixture was removed from the aggregometer cuvette and mixed w i t h 50 pl of ethanol. After rapid centrifugation, the thromboxane B, content of the supernatent was measured by radioimmunoassay (Ferraris, Smith & Silver, 1977) . We prepared 'H-labelled thromboxane B, biosynthetically in human platelets from 3H-labelled arachidonate (Granstrom, Kindahl & Samuelsson, 1976) for use as a tracer in the assay, with standards in the range 0-6 pmol. The assay showed a limit of sensitivity of 0-05 pmol.
For estimations of malondialdehyde, incubations were terminated by the addition of an equal volume of trichloroacetic acid (20%, w/v) in hydrochloric acid (0.2 molll). The tubes were centrifuged and 200 pl portions of supernatant were mixed with 200 p1 of thiobarbituric acid (0.5%, w/v) in Tris/hydrochloric acid buffer (0.1 mol/l, pH 7.0). The mixture was incubated at 7OoC for 30 min, cooled and then 1.1 ml of distilled water was added. The samples were then read in an Aminco SPF 500 spectrophotofluorimeter (532 nm excitation; 553 nm emission). In all cases, blanks were made up in solutions of the test substances used for platelet stimulation. Malondialdehyde bis-(dimethylacetal) was used as standard.
Bovine platelet microsomes were prepared by the method described by Yoshimoto, Yamamoto, Okuma & Hayaishi (1977) and were stored dry at -2OOC. Microsomes were incubated in Tris/ hydrochloric acid buffer (50 mmolll, pH 7.4) at a concentration of 1 mg/ml in the presence of methaemoglobin (2 pmolll) and tryptophan (5 mmol/l) as cofactors.
[3HlArachidonic acid (specific radioactivity 86 Ci/mmol) was purchased from The Radiochemical Centre, Amersham, Bucks, U.K. Bovine thrombin, L-adrenaline, ADP, sodium arachidonate, methaemoglobin, tryptophan and acetylsalicylic acid were obtained from Sigma Chemical Co., London, U.K. Sodium arachidonate was dissolved in sodium chloride solution (154 mmol/l) and was stored in the dark under argon at -2OOC. Solubilized collagen was purchased from Horm-Chemie, Munich, Germany and imidazole from British Drug Houses, Poole, Dorset, U.K. Malondialdehyde bis-(dimethylacetal) was supplied by Aldrich Chemical Co., Gillingham, U.K. Synthetic thromboxane B, and (15s)-hydroxy-l1~9cr-(epoxymethano)prosta-5Z, 13E-dienoic acid (U 46619) were kindly donated by Dr J.E. Pike, Upjohn Co., Kalamazoo, MI, U.S.A., and thromboxane B, antisera were a generous gift from Dr J. B. Smith, Cardeza Foundation, Philadelphia, PA, U.S.A. Fig. 1 shows the formation of thromboxane B, and malondialdehyde from exogenous arachidonate in platelet-rich plasma, gel-filtered platelets and bovine platelet microsomes. In each case, the conversion of arachidonate into thromboxane B, and malondialdehyde increased with the dose added. In platelet-rich plasma, high concentrations of arachidonate were required, presumably because of binding to plasma proteins. When gel-filtered platelets were pre-incubated for 15 min with aspirin at concentrations from 10 pmol/l to 1 mmol/l, formation of thromboxane B, from arachidonate was progressively inhibited (Fig. 2) . At the lower concentrations of aspirin, this inhibition could be partially overcome by high concentrations of arachidonate. Pre-incubation of platelets with aspirin also resulted in decreased production of malondialdehyde although, with high concentrations of arachidonate, material reacting with thiobarbituric acid continued to be produced despite total inhibition of the formation of thromboxane B,. ' The aggregation of gel-filtered platelets by .thrombin was associated with high concen-'trations of thromboxane B, and malon-,dialdehyde (Table 1) . Similarly, aggregation induced by collagen or the ionophore A 23187 was also accompanied by increased formation of thromboxane B, and malondialdehyde ( Table 1) 
Results
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The thiol group-reactive agent, N-ethylmaleimide, induced thromboxane B, and malondialdehyde production although no platelet aggregation occurred (Table 1) .
Pre-incubation of platelets for 10 min with imidazole (5 x 1OP6-5 x mol/l), a selective inhibitor of thromboxane synthetase (Needleman, Raz, Ferrendelli & Minkes, 1977) , caused an inhibition of the formation of both thromboxane B, and malondialdehyde in the presence of collagen ( Table 2) . Similar results were obtained with I-N-butylimidazole, which proved to be 10-100-fold more potent than imidazole as an inhibitor of thromboxane synthetase ( Table 2) . The amounts of thromboxane B, and malondialdehyde produced when complete irreversible platelet aggregation was induced by ADP or adrenaline were consistently low compared with the amounts produced in response to collagen or thrombin (Table 3) . Similarly, the synthetic epoxymethano-endoperoxide analogue (U 466 19) resulted in only a slight increase in production of thromboxane B, whereas malondialdehyde was not detected, presumably owing to the relative lack of sensitivity of the malondialdehyde assay (Table 3) . When thromboxane B, concentrations were plotted against those of malondialdehyde, the slopes of the regression lines were 1-11, 1.20 and 1.33 for collagen, thrombin and sodium arachidonate respectively.
Discussion
Platelet aggregation induced by thrombin or by collagen was associated with a large increase in thromboxane B, and malondialdehyde concentrations, consistent with previous suggestions that thrombin and collagen may stimulate the release of endogenous arachidonate by stimulating phospholipase A, activity (Bills et af., 1976; Blackwell, Duncombe, Flower, Parsons & Vane, 1977) . In general, the molar yields of malondialdehyde produced by intact platelets were consistently higher than those of thromboxane B,, particularly in the presence of exogenous arachidonate. In addition, production of malondialdehyde was still apparent in aspirin-treated platelets incubated with arachidonate, even though the formation of thromboxane B, had been completely blocked. A likely explanation of these findings is that the thiobarbituric acid method for malondialdehyde estimation shows poor specificity for malondialdehyde. Thus under the conditions used in these studies, cross-reactivity may occur with other oxidation products of arachidonate, expecially in the presence of high concentrations of sodium arachidonate.
We have found consistently that ADP and adrenaline, despite causing complete, irreversible platelet aggregation, induce only small increases in thromboxane B, concentrations, particularly in comparison with collagen, thrombin and A 23 187, whereas changes in malondialdehyde concentrations were often undetectable. These findings differ quantitatively from those of Smith, Ingerman & Silver (1976) , who reported a stimulation of platelet malondialdehyde synthesis by ADP as well as by adrenaline, collagen and +.
thrombin. It is possible that substantial biosynthesis of thromboxane A, is not a prerequisite for aggregation in response to ADP, or alternatively the amounts of thromboxane A, required to induce aggregation might be very small and close to the limit of sensitivity of our assay. It has been suggested that considerable quantities of thromboxane A, may become covalently bound to protein and thus not be hydrolysed to thromboxane B, (Fitzpatrick & Gorman, 1977) . This raises the possibility that mare thromboxane A, may be produced in the platelet than can be measured as thromboxane B, by radioimmunoassay, and might explain why aggregation can occur in the presence of very small amounts of measurable thromboxane B,.
Alternatively, the formation of thromboxane may only be of minor importance during aggregation induced by agents such as ADP.
The experiments with inhibitors of cyclo-oxygenase and thromboxane synthetase indicate that thromboxane B, and malondialdehyde are formed in parallel, substantiating the hypothesis that the synthesis of both substances is catalysed by thromboxane synthetase (Diczfalusy et al., 1977; McMillan et al., 1978) . However, the results strongly suggest that the thiobarbituric acid method for the estimation of malondialdehyde can also be used to detect other products of lipid metabolism. This apparent lack of specificity of the malondialdehyde assay renders it less useful than the radioimmunoassay for thromboxane B, as an index of platelet thromboxane bio-,synthesis.
